Clinical Scorecard: FDA adds generic valganciclovir oral solution
At a Glance
| Category | Detail |
|---|---|
| Condition | Cytomegalovirus (CMV) infection, including CMV retinitis and CMV disease in transplant recipients |
| Key Mechanisms | Valganciclovir is an antiviral indicated for CMV retinitis treatment in adults with AIDS and CMV disease prevention in specified high-risk transplant recipients. |
| Target Population | Adults with AIDS and high-risk kidney, heart, or kidney-pancreas transplant recipients; reference-product labeling also includes pediatric kidney and heart transplant recipients. |
| Care Setting | Prescription treatment and prophylaxis; the oral solution must be prepared by a pharmacist before dispensing. |
Key Highlights
- FDA granted final approval to a generic valganciclovir oral solution, 50 mg/mL, through the abbreviated new drug application pathway.
- The generic is therapeutically equivalent to Valcyte for Oral Solution, the reference-listed product.
- The approval announcement reported no new clinical efficacy or safety findings.
- Valganciclovir carries boxed warnings for hematologic toxicity, impaired fertility, fetal toxicity, mutagenesis, and carcinogenesis.
Guideline-Based Recommendations
Diagnosis
Management
- Valganciclovir is indicated for CMV retinitis treatment in adults with AIDS and CMV disease prevention in high-risk kidney, heart, and kidney-pancreas transplant recipients.
- Reference-product labeling includes prophylaxis for pediatric kidney transplant recipients aged 4 months to 16 years and heart transplant recipients aged 1 month to 16 years.
- Administer the oral solution with food; a pharmacist must prepare it before dispensing.
- Adults should use valganciclovir tablets rather than oral solution unless they are unable to swallow tablets.
- Individualize pediatric prophylaxis dosing according to body surface area and renal function.
Monitoring & Follow-up
- Monitor blood counts and renal function.
- Adjust the dose in patients with renal impairment.
Risks
- Boxed warnings include hematologic toxicity, impairment of fertility, fetal toxicity, mutagenesis, and carcinogenesis.
- Clinically significant adverse effects include neutropenia, anemia, and thrombocytopenia.
Patient & Prescribing Data
Adults with AIDS being treated for CMV retinitis; high-risk kidney, heart, and kidney-pancreas transplant recipients receiving CMV disease prevention; and pediatric kidney or heart transplant recipients covered by reference-product labeling.
The approved generic oral solution is 50 mg/mL. High-risk transplant recipients include CMV-seronegative recipients of organs from CMV-seropositive donors. Administer with food; monitor blood counts and renal function, and adjust dosing for renal impairment.
Clinical Best Practices
- Use the oral solution in adults only when they are unable to swallow tablets, according to the reference product's labeling.
- Ensure the solution is prepared by a pharmacist before dispensing.
- For pediatric prophylaxis, individualize dosing based on body surface area and renal function.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
